Work

Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.e13559

Authors: Udai Banerji, Alan David Smith, Andrea Zivi, David Lorente, Karim Rihawi, Nina Tunariu, Adam Stewart, Parames Thavasu, Audrey Kaag, Rajkumar Radhakrishnan, Heiko Maacke, L Rhoda Molife, Stanley B. Kaye, Johann Sebastian De Bono

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Novartis (Switzerland), Novartis (India)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2766580713

Cites:

Cited by: 3

Related to: 10